Chimeric Therapeutics (ASX:CHM) said that the US Food and Drug Administration (FDA) granted fast-track designation to its CHM CDH17 chimeric antigen receptor T-cell (CAR-T) therapy for treating advanced gastroenteropancreatic neuroendocrine tumors in patients who have progressed after prior treatment, according to a Wednesday filing with the Australian bourse.
Fast-track designation aims to expedite the development and review of treatments for serious conditions with unmet needs, providing increased interaction with the US FDA and potential eligibility for a priority review and a rolling biologics license application review, the filing said.
CHM CDH17 is currently in a trial phase assessing safety and efficacy in advanced colorectal, gastric, and intestinal neuroendocrine cancers, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.